Early diabetic nephropathy and cardiovascular disease in a Mediterranean population: Risk factors and treatment intensity;Nefropatía diabética inicial y enfermedad cardiovascular en una población mediterránea: Factores de riesgo y grado de tratamiento

Revista Clinica Espanola

Volumn 204, Issue 5, 2004, Pages 255-259

  Perez Maraver M ^a   Carrera Santaliestra, M J ^a   Vinzia Uriach, G ^b   Micalo Duran T ^c   Gomez Arnaiz N ^d   Sahun de la Vega M ^e   Soler Ramon J ^a   Montanya Mias E ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b ABS Just Oliveres   (Spain)

^c Hospital Sant Llorenç   (Spain)

^d ABS Ramona   (Spain)

^e ICS   (Spain)

Author keywords

Cardiovascular disease; Diabetic nephropathy; Mediterranean population; Therapeutic objectives

Indexed keywords

CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION; PRACTICE GUIDELINE; PREVALENCE; RISK FACTOR; SMOKING; SOUTHERN EUROPE;

EID: 2942537828     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1157/13061411     Document Type: Article

References (30)

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA 1979;241:2035-8.
2. Mattock MB, Morrish NJ, Viberti G, Keen H, Fitzgerald AP, Jackson G. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 1992;41:736-41.
3. Morrish NJ, Stevens LK, Head J, Fuller JH, Jarrett RJ, Keen H. A prospective study of mortality among middle-aged diabetic patients (the London cohort of the WHO multinational study of vascular disease in diabetics) II: associated risk factors. Diabetología 1990; 33:542-8.
4. Natali A, Vichi S, Landi P, Severi S, L'Abbate A, Ferrannini E. Coronary atherosclerosis in type 2 diabetes: angiographic findings and clinical outcome. Diabetología 2000;43:632-41.
5. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. Arch Intern Med 1997;157:1413-8.
6. Ismail N, Becker B, Strzelczyk P, Ritz E. Renal disease and hypertension in non-insulin dependent diabetes mellitus. Kidney Int 1999;55:1-28.
7. Tunstall-Pedoe H, Kuulasmaa K, Mahönën M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-years results from 37 WHO MONICA project populations. Lancet 1999;353:1547-57.
8. Van den Hoogen P, Feskens E, Nagelkerke N, Menotti A, Nissinen A, Kromhout D. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. N Engl J Med 2000;342:1-8.
9. Verschuren WMM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures: twenty-five-year follow-up of the Seven Countries Study. JAMA 1995;274: 131-6.
10. Ryan M, McInerney D, Owens D, Collins P, Johnson A, Tomkin GH. Diabetes and the mediterranean diet: a beneficial effect of oleic acid on insulin sensitivity, adipocite glucose transport and endothelium-dependent vasoreactivity. QJM 2000;93(2):85-91.
11. Plans P, Pardell H, Salleras L. Epidemilogy of cardiovascular risk factors in Catalonia (Spain). Eur J Epidemiol 1993;9(4):381-9.
12. Esmatjes E, Castell C, González T, Tresserras R, Lloveras G. Epidemiology of renal involvement in type II diabetics (NIDDM) in Catalonia. Diabetes Res Clin Prac 1996; 32:157-63.
13. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28:1039-57.
14. Sheps SG. Overview of JNC VI: new directions in the management of hypertension and cardiovascular risk. Am J Hypertens 1999;12:65S-72S.
15. Executive Summary of the Third Report of the National Colesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood colesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
16. Donn EJ, Burton CJ, Feest TG. The care of patients with diabetic nephropathy: audit, feedback, and improvement. QJM 1999;92(8):443-9.
17. MacLeod JM, Lutale J, Marshall SM. Albumin excretion and vascular deaths in NIDDM. Diabetología 1995;38:610-6.
18. Orth SR, Ritz E, Schrier RW. The renal risks of smoking. Kidney Int 1997;51:1669-77.
19. UK Prospective Diabetes Study (UKPDS) group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352(9131):837-53.
20. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9.
21. The long-term intervention with pravastatin in ischaemic disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998:339:1349-57.
22. White HD, Simes RJ, Anderson NE, Hankey GJ, Watson JD, Hunt D, et al. Pravastatin therapy and the risk of stroke. N Engl J Med 2000; 343:317-26.
23. Hansson L, Zanchetti A, Carruthers G, Dabolf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755-62.
24. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/β-blocker-based treatment regimen. Diabetes Care 2001:24:2091-6.
25. Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antinainen R, Bulpitt CJ, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999;340:677-84.
26. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-34.
27. Berlowitz DR, Ash A, Hickey EC, Friedman RM, Glickman M, Kader B, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998;339:1957-63.
28. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001;345:479-86.
29. Frolkis JP, Zyzanski,SJ, Schwartz JM, Suhan PS. Physician noncompliance with the 1993 national cholesterol education program (NCEP-ATPII) guidelines. Circulation 1998;98:851-5.
30. Grupo de Investigación del Estudio Elipse. Prevención secundaria de la cardiopatía isquémica en la provincia de Ciudad Real. Efectividad de la terapéutica hipolipidemiante en Atención Primaria. Med Clin (Barc) 2000;115: 321-5.